Sarepta Therapeutics Stock
€17.25
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Sarepta
sharewise wants to provide you with the best news and tools for Sarepta, so we directly link to the best financial data sources.
Financials
News
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
For Sarepta Therapeutics (NASDAQ: SRPT), 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment
Sarepta Therapeutics Stock: FDA Reverses Course on Therapy Ban
Sarepta Therapeutics has experienced a whirlwind week as the FDA unexpectedly reversed its recommendation to suspend shipments of Elevidys, the company's gene therapy for Duchenne muscular
Sarepta Therapeutics Stock: FDA Action Triggers 90% Collapse
Sarepta Therapeutics shares have plummeted to just around $14, representing a catastrophic decline of over 90% in the past year. The devastating selloff follows the FDA's request for a voluntary
Sarepta Therapeutics Stock: Crisis Deepens After Third Death
Sarepta Therapeutics continues its downward spiral after a third patient death was reported in clinical trials, sending the stock plummeting to $18.21 - representing an 84.7% decline over the past
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this
Can Solid Biosciences Challenge Sarepta in the DMD Market?
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. It usually first shows up in boys aged two to five years. Genetic alterations
Is This Stock a Buy After Soaring by 20% in 1 Day?
It's been a rough year for Sarepta Therapeutics (NASDAQ: SRPT), a small-cap biotech that develops medicines for rare diseases. The company's shares are down by 88% year to date due to safety issues
2 Beaten-Down Stocks to Avoid
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2024 Earnings CallFeb 26, 2025, 4:30 p.m. ET
Operator
Source Fool.com